Sugi Predict

Sugi Predict / Compounds / SCHEMBL1360465

SCHEMBL1360465

SCHEMBL1360465

CC1(C)OB(c2cccnc2OCc2ccccc2)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.47
▸ LTA4H P09960 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ CNR2 P34972 4/20 0.38
▸ CNR1 P21554 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ATP4A P20648 1/20 0.37
▸ ATP4B P51164 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29900384 0.82 L3MBTL1 (0.36) NPC1L3MBTL1ALDH1A1LMNAHPGD
SCHEMBL365301 0.82 L3MBTL1 (0.36) NPC1L3MBTL1ALDH1A1LMNAHPGD
SCHEMBL29199672 0.82 CNR2 (0.39) DGAT1LTA4HMAPK14MEN1NPC1
SCHEMBL1360468 0.81 TDP1 (0.44) DGAT1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL25482311 0.81 DGAT1 (0.46) DGAT1L3MBTL1ALDH1A1LMNAHPGD
SCHEMBL19585801 0.81 DGAT1 (0.46) DGAT1L3MBTL1ALDH1A1LMNAHPGD
SCHEMBL29532520 0.81 DGAT1 (0.46) DGAT1L3MBTL1ALDH1A1LMNAHPGD
SCHEMBL30138169 0.80 LPL (0.36) DGAT1NPC1RAB9AALDH1A1HPGD
SCHEMBL9998673 0.80 LPL (0.36) DGAT1NPC1RAB9AALDH1A1HPGD
SCHEMBL19830896 0.80 DGAT1 (0.48) DGAT1MEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118255780-A Compound for inhibiting and degrading c-MYC and medical application thereof 西藏海思科制药有限公司 2024-06-28 — — CN disclosed
CN-118146224-A Nitrogen-containing tricyclic derivative and application thereof in medicine 西藏海思科制药有限公司 2024-06-07 — — CN disclosed
CN-116261458-B PLK1 degradation inducing compounds 厄普特拉株式会社 2024-05-24 — — CN disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 — — CN disclosed
CN-117940414-A Compounds for targeting IRAK4 protein degradation 渤健马萨诸塞州股份有限公司 2024-04-26 — — CN disclosed
CN-117940133-A Therapeutic agents for degradation of mutant BRAF C4医药公司 2024-04-26 — — CN disclosed
CN-117916231-A Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same 纽力克斯治疗公司 2024-04-19 — — CN disclosed
CN-117897385-A Compound for degrading Bcl-2 family proteins and application of compound in medicine 西藏海思科制药有限公司 2024-04-16 — — CN disclosed
CN-117858874-A HPK1 degrading agents, compositions comprising the same, and methods of use thereof 百放开曼有限公司 2024-04-09 — — CN disclosed
CN-117813307-A Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof 新锐思生物制药股份有限公司 2024-04-02 — — CN disclosed
CN-111615514-A Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors 奥瑞生物药品公司 2020-09-01 — — CN disclosed
WO-2019143994-A1 SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2019-07-25 — — WO disclosed
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 — — US disclosed
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 — — US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 — — EP disclosed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 — — EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 — — US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 — — WO disclosed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 — — US disclosed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B DGAT1 2717/4885LTA4H 3393/4885MAPK14 3877/4885
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS DGAT1 2149/4885LTA4H 3592/4885MAPK14 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.